Latest news with #PharmaJet
Business Wire
6 hours ago
- Health
- Business Wire
WHO and UNICEF to Launch Polio Vaccination Campaign in Afghanistan with PharmaJet
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign sponsored by the National Emergency Operation Center (NEOC) Afghanistan, UNICEF, WHO, and other GPEI partners starting in August 2025. Focused on the Eastern region of Afghanistan, the campaign will deploy Tropis ID to administer 1.3 million fractional doses of inactivated polio vaccine (fIPV) to children ages 5 and under in parallel to oral polio vaccine (OPV) administration as part of a WHO-recommended strategy to boost humoral and mucosal immunity. Poliovirus has been eliminated in most parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. This approach is expected to help increase immunization coverage, particularly in high-risk areas. The Technical Advisory Group (TAG) on polio eradication endorsed the Afghanistan program's 'Strategic Reset' to optimize site-to-site vaccination, while stressing the need for stronger leadership, community acceptance, and broad government engagement. Including Tropis ID fIPV in this immunization program supports Afghanistan's polio eradication goals to eliminate persistent virus lineages in the East, prevent new WPV1 cases in the East and South Regions, and prevent local transmission in other parts of the country. 1 'We are pleased to be partnering with UNICEF, WHO, and NEOC Afghanistan in their continued efforts to eradicate polio,' said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. 'We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability 2 previously seen with Tropis ID delivered fIPV in Pakistan, 2 Somalia, 3 and Nigeria 4.' Refer to Instructions for Use to ensure safe injections and to review risks. About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About the NEOC Afghanistan NEOC Afghanistan is led by the Ministry of Public Health and the core members are WHO, UNICEF, BMGF, CDC, Rotary International, Core Group of Polio Project (CGPP), EPI manager and the National Polio Focal Point. About the Global Polio Eradication Initiative (GPEI) 5 The Global Polio Eradication Initiative is a public-private partnership led by national governments with six partners – the World Health Organization (WHO), Rotary International, the US Centers for Disease Control and Prevention (CDC), the United Nations Children's Fund (UNICEF), Gates Foundation and Gavi, the vaccine alliance. Its goal is to eradicate polio worldwide. Launched in 1988 after the World Health Assembly passed a resolution to eradicate polio, the Global Polio Eradication Initiative, along with its partners, has helped countries to make huge progress in protecting the global population from this debilitating disease. As a result, the global incidence of polio has decreased by 99.9% since GPEI's foundation. An estimated 20 million people today are walking who would otherwise have been paralyzed by the disease, and more than 1.5 million people are alive, whose lives would otherwise have been lost. Now the task remains to tackle polio in its last few strongholds and get rid of the final 0.1% of polio cases including the two remaining endemic countries: Pakistan and Afghanistan.
Yahoo
12 hours ago
- Health
- Yahoo
WHO and UNICEF to Launch Polio Vaccination Campaign in Afghanistan with PharmaJet® Tropis® ID Delivery System
PharmaJet has been awarded a UNICEF tender to support WHO and GlobalPolio Eradication Initiative (GPEI) partners. This is the first large-scale implementation of intradermal (ID) polio immunization in Afghanistan. PharmaJet's award builds on the successful implementation of Tropis for ID delivery in polio vaccination campaigns in Pakistan, Nigeria, and Somalia. The use of Tropis ID in polio vaccination campaigns has improved vaccine coverage, decreased immunization program costs, and increased acceptability. GOLDEN, Colo., August 19, 2025--(BUSINESS WIRE)--PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign sponsored by the National Emergency Operation Center (NEOC) Afghanistan, UNICEF, WHO, and other GPEI partners starting in August 2025. Focused on the Eastern region of Afghanistan, the campaign will deploy Tropis ID to administer 1.3 million fractional doses of inactivated polio vaccine (fIPV) to children ages 5 and under in parallel to oral polio vaccine (OPV) administration as part of a WHO-recommended strategy to boost humoral and mucosal immunity. Poliovirus has been eliminated in most parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. This approach is expected to help increase immunization coverage, particularly in high-risk areas. The Technical Advisory Group (TAG) on polio eradication endorsed the Afghanistan program's "Strategic Reset" to optimize site-to-site vaccination, while stressing the need for stronger leadership, community acceptance, and broad government engagement. Including Tropis ID fIPV in this immunization program supports Afghanistan's polio eradication goals to eliminate persistent virus lineages in the East, prevent new WPV1 cases in the East and South Regions, and prevent local transmission in other parts of the country.1 "We are pleased to be partnering with UNICEF, WHO, and NEOC Afghanistan in their continued efforts to eradicate polio," said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. "We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability2 previously seen with Tropis ID delivered fIPV in Pakistan,2 Somalia,3 and Nigeria4." Refer to Instructions for Use to ensure safe injections and to review risks. About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About the NEOC Afghanistan NEOC Afghanistan is led by the Ministry of Public Health and the core members are WHO, UNICEF, BMGF, CDC, Rotary International, Core Group of Polio Project (CGPP), EPI manager and the National Polio Focal Point. About the Global Polio Eradication Initiative (GPEI)5 The Global Polio Eradication Initiative is a public-private partnership led by national governments with six partners – the World Health Organization (WHO), Rotary International, the US Centers for Disease Control and Prevention (CDC), the United Nations Children's Fund (UNICEF), Gates Foundation and Gavi, the vaccine alliance. Its goal is to eradicate polio worldwide. Launched in 1988 after the World Health Assembly passed a resolution to eradicate polio, the Global Polio Eradication Initiative, along with its partners, has helped countries to make huge progress in protecting the global population from this debilitating disease. As a result, the global incidence of polio has decreased by 99.9% since GPEI's foundation. An estimated 20 million people today are walking who would otherwise have been paralyzed by the disease, and more than 1.5 million people are alive, whose lives would otherwise have been lost. Now the task remains to tackle polio in its last few strongholds and get rid of the final 0.1% of polio cases including the two remaining endemic countries: Pakistan and Afghanistan. 1 World Health Organization, Global Polio Eradication Initiative, Technical Advisory Group urges strong action to eradicate polio in Afghanistan, February 26, 20252 Daly, C et al, Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, Vaccine, Volume 38 Issue 8, 18 February, 2020, Pages 1893-18983 Nouh, K et al, Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia, Springer Nature Volume 2 article number 16 (2024)4 Biya, O et al, Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine — Sokoto State, Nigeria, November 2022, CDC Morbidity and Mortality Weekly report, November 24, 2023 / 72(47);1290–12915 Global Polio Eradication Initiative, who we are: View source version on Contacts Nancy 1-888-900-4321 Option 3
Business Wire
15 hours ago
- Health
- Business Wire
WHO and UNICEF to Launch Polio Vaccination Campaign
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign sponsored by the National Emergency Operation Center (NEOC) Afghanistan, UNICEF, WHO, and other GPEI partners starting in August 2025. Focused on the Eastern region of Afghanistan, the campaign will deploy Tropis ID to administer 1.3 million fractional doses of inactivated polio vaccine (fIPV) to children ages 5 and under in parallel to oral polio vaccine (OPV) administration as part of a WHO-recommended strategy to boost humoral and mucosal immunity. Poliovirus has been eliminated in most parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. This approach is expected to help increase immunization coverage, particularly in high-risk areas. The Technical Advisory Group (TAG) on polio eradication endorsed the Afghanistan program's 'Strategic Reset' to optimize site-to-site vaccination, while stressing the need for stronger leadership, community acceptance, and broad government engagement. Including Tropis ID fIPV in this immunization program supports Afghanistan's polio eradication goals to eliminate persistent virus lineages in the East, prevent new WPV1 cases in the East and South Regions, and prevent local transmission in other parts of the country. 1 'We are pleased to be partnering with UNICEF, WHO, and NEOC Afghanistan in their continued efforts to eradicate polio,' said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. 'We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability 2 previously seen with Tropis ID delivered fIPV in Pakistan, 2 Somalia, 3 and Nigeria 4.' Refer to Instructions for Use to ensure safe injections and to review risks. About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About the NEOC Afghanistan NEOC Afghanistan is led by the Ministry of Public Health and the core members are WHO, UNICEF, BMGF, CDC, Rotary International, Core Group of Polio Project (CGPP), EPI manager and the National Polio Focal Point. About the Global Polio Eradication Initiative (GPEI) 5 The Global Polio Eradication Initiative is a public-private partnership led by national governments with six partners – the World Health Organization (WHO), Rotary International, the US Centers for Disease Control and Prevention (CDC), the United Nations Children's Fund (UNICEF), Gates Foundation and Gavi, the vaccine alliance. Its goal is to eradicate polio worldwide. Launched in 1988 after the World Health Assembly passed a resolution to eradicate polio, the Global Polio Eradication Initiative, along with its partners, has helped countries to make huge progress in protecting the global population from this debilitating disease. As a result, the global incidence of polio has decreased by 99.9% since GPEI's foundation. An estimated 20 million people today are walking who would otherwise have been paralyzed by the disease, and more than 1.5 million people are alive, whose lives would otherwise have been lost. Now the task remains to tackle polio in its last few strongholds and get rid of the final 0.1% of polio cases including the two remaining endemic countries: Pakistan and Afghanistan. 1 World Health Organization, Global Polio Eradication Initiative, Technical Advisory Group urges strong action to eradicate polio in Afghanistan, February 26, 2025 2 Daly, C et al, Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, Vaccine, Volume 38 Issue 8, 18 February, 2020, Pages 1893-1898 3 Nouh, K et al, Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia, Springer Nature Volume 2 article number 16 (2024) 4 Biya, O et al, Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine — Sokoto State, Nigeria, November 2022, CDC Morbidity and Mortality Weekly report, November 24, 2023 / 72(47);1290–1291 5 Global Polio Eradication Initiative, who we are:
Yahoo
10-07-2025
- Health
- Yahoo
PharmaJet® Enters into MOU Agreement with Egyptian UPA and EVA Pharma to provide Needle-Free Delivery for Routine Immunization in Egypt
Advancing Equitable Immunization Through Technology Transfer and Localized Needle-Free Injection Manufacturing GOLDEN, Colo. & CAIRO, July 10, 2025--(BUSINESS WIRE)--PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has signed a Memorandum of Understanding (MOU) agreement with the Egyptian Unified Procurement Authority (UPA) and EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, to explore the integration of needle-free delivery of inactivated polio vaccine into Egypt's routine immunization program. The signing event took place in Cairo at the African Health ExCon healthcare conference on June 26. The agreement includes provisions for distribution, technology transfer, manufacturing, and new pharmaceutical product development, as well as collaborating to increase needle-free access within Egypt and regionally. The UPA seeks to incorporate new technologies into its portfolio, aiming to expand the benefits of vaccination against certain infectious agents, improve pandemic preparedness, reduce total immunization costs, and improve foreign exchange rates. Tropis® Needle-free adoption offers several strategic advantages for Egypt including substantial immunization cost savings of 38% or more over six years1, reduced vaccine hesitancy2,3, increased coverage2, and the potential for medical technology localization. EVA Pharma is a leading pharmaceuticals and medical appliances manufacturing company that has vast experience in manufacturing, registering, marketing, and promoting pharmaceutical products. "This collaboration can transform immunization by making it safer, more accessible, and less painful for children and caregivers," said Nicolas Boege, Director of Global Commercial & Corporate Development at EVA Pharma. "By introducing this technology, alongside localized technology transfer and manufacturing, EVA Pharma is committed to scaling innovation that strengthens public health systems. We are proud to collaborate with UPA and PharmaJet to localize needle-free delivery and accelerate its integration into Egypt's immunization programs and beyond." The adoption and introduction of Tropis with concurrent manufacturing technology transfer has the potential to advance UPA's goal of becoming the leader of immunization excellence and a hub of needle-free product manufacturing for the Middle East and Northern Africa. The current initiative will enhance pandemic preparedness, reduce immunization costs, and support Egypt's Universal Health Insurance project. It also emphasizes the critical importance of the first 1,000 days in a child's life, building on the earlier efforts of the '1000 Golden Days' presidential initiative. "This collaboration with UPA and EVA Pharma has the potential to enable the children of Egypt to gain from the benefits of intradermal (ID) delivery with reduced pain and administration time. The UPA would benefit through cost savings and novel pharma product development and manufacturing opportunities with needle-free delivery, and we would be thrilled to expand PharmaJet's commercial applications into Egypt and regionally. It's a win-win all around," said Paul LaBarre, Vice President of Business Development for PharmaJet. "We look forward to contributing to early childhood development in this region by increasing the positive impact of needle-free immunization." Tropis ID has been widely used for inactivated polio vaccine delivery in campaigns and supplemental immunization activities. It has been rigorously evaluated in a routine immunization setting in two recently published studies that showed greater than 94% acceptability amongst healthcare workers and caregivers3, reduced administration time3, and greater than 50% reduction in immunization adverse events compared with intradermal delivery with a needle4. Refer to Instructions for Use to ensure safe injections and to review risks. 1 Data on file2 Soonawala, D et al, Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults, Vaccine, Volume 31, Issue 36, 12 August 2013, Pages 3688-36943 Mohan, D et al, Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial , Vaccines,16 May 2025, 13(5), p.5334 Resik, S et al, Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immunization services in Cuba. Vaccine, Volume 52 (2025), 126903 About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. Tropis® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About The Egyptian Unified Procurement Authority (UPA) The Egyptian Unified Procurement Authority (UPA) is a government entity established to streamline and enhance the procurement of medical supplies, pharmaceuticals, and healthcare technologies in Egypt. Its primary goal is to improve the efficiency and effectiveness of the healthcare sector by ensuring timely and cost-effective acquisition of necessary resources. The UPA is a key component of Egypt's 2030 Vision for universal health coverage. About EVA Pharma EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic products. With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies. Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company's product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand. EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide. For more information, please visit: View source version on Contacts Nancy 1-888-900-4321 Option 3Marina
Associated Press
19-06-2025
- Health
- Associated Press
PharmaJet® and Immuno Cure Sign Agreement for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine
GOLDEN, Colo.--(BUSINESS WIRE)--Jun 19, 2025-- PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has entered into an agreement with Immuno Cure, a prominent developer of DNA vaccines. Under the terms of the agreement, Immuno Cure will use PharmaJet's Tropis ID system in a human clinical trial to deliver their novel HIV-1 therapeutic DNA Vaccine (ICVAX). The agreement was executed on June 16, 2025, during a signing ceremony at the 2025 BIO International Convention in Boston, Massachusetts. This press release features multimedia. View the full release here: Dr. Xia Jin, CEO and Co-Founder of Immuno Cure, and Mr. Dan Mallon, Senior Vice President of Corporate Development of PharmaJet, captured the memorable moment after signing the MTA 'HIV Therapeutic DNA Vaccine (ICVAX) Clinical Study'. The study follows the successful first-in-human ICVAX Phase 1 clinical trial that showed exceptional safety and promising immunogenicity profiles. 3 The vaccine represents a significant step towards achieving virological control by ICVAX without antiretroviral therapy and ultimately becoming a functional cure of human immunodeficiency virus (HIV)/AIDS. Immuno Cure is investigating the potential for the Tropis ID system to improve the DNA vaccine performance and patient's clinical experience. Intradermal delivery is expected to help elicit long-lived and cross-reactive immune responses. The Tropis system easily leverages the rich network of dendritic cells, macrophages and T cells in the dermal layer and can provide a more potent and broader immunogenic response than vaccinating into the muscle. 1 Tropis is commercially scaled, has been used for over 12 million injections, and is the first and only needle-free ID delivery technology to achieve World Health Organization (WHO) prequalification. Dr. Xia Jin MD PhD, CEO of Immuno Cure, said, 'At Immuno Cure, our mission is to advance transformative therapies for infectious diseases and cancer. We are excited to partner with PharmaJet and leverage their Tropis Needle-free Injection System on our HIV therapeutic DNA vaccine program. We value innovative approaches that could enhance patient experience and vaccine performance.' 'This agreement adds to our portfolio of global development partnerships with innovative oncology and infectious disease developers. Our partners are joining our call to challenge antiquated IM administration methods in favor of ID delivery based on the growing body of evidence 4 demonstrating improved immune responses and safety profiles,' said Dan Mallon, Senior Vice President Corporate Development, PharmaJet. 'PharmaJet's needle-free technology is safe and well-tolerated and has shown to enable immune responses that are robust and durable.' Refer to Instructions for Use to ensure safe injections and to review risks. About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. Tropis ® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About Immuno Cure Immuno Cure is a clinical-stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight against cancers, inflammatory and infectious diseases based on its patented PD-1-Enhanced DNA Vaccine, Anti-Δ42PD1 Antibody and Vaccine Delivery Platform. To learn more about Immuno Cure, please visit: View source version on CONTACT: Nancy Lillie [email protected] 1-888-900-4321 Option 3 KEYWORD: HONG KONG UNITED STATES NORTH AMERICA ASIA PACIFIC MASSACHUSETTS COLORADO INDUSTRY KEYWORD: MEDICAL DEVICES INFECTIOUS DISEASES GENETICS CLINICAL TRIALS HEALTH TECHNOLOGY BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH ONCOLOGY SOURCE: PharmaJet Copyright Business Wire 2025. PUB: 06/19/2025 10:10 AM/DISC: 06/19/2025 10:09 AM
